Lantheus Holdings Inc. has agreed to be acquired by Curium, a radiopharmaceutical company supported by CapVest Partners. The transaction, worth up to $8 billion, combines immediate cash and potential future payments.
Under the agreement, Curium US will purchase all remaining Lantheus shares for $102.50 each in cash, plus non-transferable Contingent Value Rights of up to $12 per share. The full package of up to $114.50 per share offers a 38% increase above Lantheus' 60-day volume-weighted average price.
The deal will be funded entirely by a blend of debt and equity, without requiring additional financing. Completion is scheduled for the first half of 2027, forming a combined business focused on radiodiagnostics and theranostics.
Lantheus will provide its U.S. commercial operations and its F-18 prostate diagnostics line, including PYLARIFY. Curium will add its global production capabilities and a range of radioligand therapies.
The new company will deliver services to oncology, neurology, and cardiology patients in more than 70 countries. Lantheus will keep functioning as a public company until the acquisition finalizes.
Before market opened on Nasdaq, Lantheus stock climbed 2.88% to $102.51. Morgan Stanley, BofA Securities, and Solomon Partners represented Lantheus, while Jefferies, J.P. Lantheus plans to release its second quarter 2026 results on August 6, offering insights ahead of the deal closing.